ENTERA BIO LTD. Operating Expenses
ENTERA BIO LTD. (ENTX) reported Operating Expenses of $4.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-07
- ENTERA BIO LTD. operating expenses for the quarter ending 2026-06-30 was $4.56M, a 71.03% increase year-over-year.
- ENTERA BIO LTD. operating expenses for the quarter ending 2026-03-31 was $3.54M, a 38.08% increase year-over-year.
- ENTERA BIO LTD. operating expenses for the quarter ending 2025-12-31 was $3.04M, a 30.17% increase year-over-year.
- ENTERA BIO LTD. operating expenses for the quarter ending 2025-09-30 was $3.26M, a 7.78% increase year-over-year.
- ENTERA BIO LTD. operating expenses for fiscal 2025 was $11.53M, a 20.17% increase from fiscal 2024.
- ENTERA BIO LTD. operating expenses for fiscal 2024 was $9.59M, a 7.91% increase from fiscal 2023.
- ENTERA BIO LTD. operating expenses for fiscal 2023 was $8.89M, a 31.87% decline from fiscal 2022.
- ENTERA BIO LTD. operating expenses for fiscal 2022 was $13.05M, a 5.11% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.56M 10-Q · filed 2026-08-07 | $8.10M 10-Q · filed 2026-08-07 | $11.14M derived: sum of 3 quarters · filed 2026-08-07 | $14.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $3.54M 10-Q · filed 2026-05-08 | $6.58M derived: sum of 2 quarters · filed 2026-05-08 | $9.84M derived: sum of 3 quarters · filed 2026-05-08 | $12.51M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $6.30M derived: sum of 2 quarters · filed 2026-03-27 | $8.97M derived: sum of 3 quarters · filed 2026-08-07 | $11.53M 10-K · filed 2026-03-27 |
| 2025-09-30 | $3.26M 10-Q · filed 2025-11-14 | $5.92M derived: sum of 2 quarters · filed 2026-08-07 | $8.49M 10-Q · filed 2025-11-14 | $10.82M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $2.67M 10-Q · filed 2026-08-07 | $5.23M 10-Q · filed 2026-08-07 | $7.57M derived: sum of 3 quarters · filed 2026-08-07 | $10.59M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $2.56M 10-Q · filed 2026-05-08 | $4.90M derived: sum of 2 quarters · filed 2026-05-08 | $7.92M derived: sum of 3 quarters · filed 2026-05-08 | $10.10M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $5.36M derived: sum of 2 quarters · filed 2026-03-27 | $7.53M derived: sum of 3 quarters · filed 2026-03-27 | $9.59M 10-K · filed 2026-03-27 |
| 2024-09-30 | $3.02M 10-Q · filed 2025-11-14 | $5.20M derived: sum of 2 quarters · filed 2025-11-14 | $7.26M 10-Q · filed 2025-11-14 | $9.22M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.17M 10-Q · filed 2025-08-08 | $4.24M 10-Q · filed 2025-08-08 | $6.20M derived: sum of 3 quarters · filed 2025-08-08 | $8.59M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $2.06M 10-Q · filed 2025-05-09 | $4.03M derived: sum of 2 quarters · filed 2025-05-09 | $6.41M derived: sum of 3 quarters · filed 2025-05-09 | $8.74M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $4.35M derived: sum of 2 quarters · filed 2025-03-28 | $6.68M derived: sum of 3 quarters · filed 2025-03-28 | $8.89M 10-K · filed 2025-03-28 |
| 2023-09-30 | $2.39M 10-Q · filed 2024-11-08 | $4.72M derived: sum of 2 quarters · filed 2024-11-08 | $6.93M 10-Q · filed 2024-11-08 | $10.00M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $2.33M 10-Q · filed 2024-08-09 | $4.54M 10-Q · filed 2024-08-09 | $7.62M derived: sum of 3 quarters · filed 2024-08-09 | $10.48M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $2.21M 10-Q · filed 2024-05-10 | $5.29M derived: sum of 2 quarters · filed 2024-05-10 | $8.15M derived: sum of 3 quarters · filed 2024-05-10 | $11.41M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $5.94M derived: sum of 2 quarters · filed 2024-03-08 | $9.20M derived: sum of 3 quarters · filed 2024-03-08 | $13.05M 10-K · filed 2024-03-08 |
| 2022-09-30 | $2.87M 10-Q · filed 2023-11-14 | $6.13M derived: sum of 2 quarters · filed 2023-11-14 | $9.98M 10-Q · filed 2023-11-14 | $14.09M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $3.26M 10-Q · filed 2023-08-11 | $7.11M 10-Q · filed 2023-08-11 | $11.23M derived: sum of 3 quarters · filed 2023-08-11 | $14.52M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $3.85M 10-Q · filed 2023-05-05 | $7.97M derived: sum of 2 quarters · filed 2023-05-05 | $11.26M derived: sum of 3 quarters · filed 2023-05-05 | $13.84M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $7.41M derived: sum of 2 quarters · filed 2023-03-31 | $9.99M derived: sum of 3 quarters · filed 2023-03-31 | $12.41M 10-K · filed 2023-03-31 |
| 2021-09-30 | $3.29M 10-Q · filed 2022-11-10 | $5.88M derived: sum of 2 quarters · filed 2022-11-10 | $8.30M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $2.58M 10-Q · filed 2022-08-11 | $5.00M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $2.42M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $11.23M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |